

age copy

Form PTO-1449

communication to applicant.

## U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. Ser. 0575/62683/JPW/JML 09/

Serial No. 09/648,389

Applicant David J.

(Use several sheets if necessary)

David J. Pinsky, et al.
Filing Date

August 25, 2000

Group

JUN 1 1 2001		3	August 25, 2000											
	<u>⊤.√8</u>	1					_		ATENT DOCU		· · · · · · · · · · · · · · · · · · ·	<del></del>		
Many ippano	MARK	D	Document Number					Date	Name	Class	Subclass	Filing Date if Appropriate		
		Т	Т	Τ	Τ		$\top$					рр. ор		
	1			+	<del>                                     </del>		+-					_	·	
	1		+	+	╁┈	<del>                                     </del>	<del>-  -</del> -							
	<del> </del>		+	+	╫	$\vdash$						-		
			+	+	+-		-		-2					
	l			<u> </u>	.L			ODEICE	N DATENT DO	CHATENIES	1	<u> </u>		
	1				NT.			Т	N PATENT DO	··· - [ ··· · · · · · · · · · · · · · ·		Tr .		
		Do	Document Number					Date	Country	Class	Subclass	Translation		
	<u> </u>		T -	<del></del>	1						<u> </u>	Yes	No	
	-		_		<u> </u>		-							
	ļ			1		<u> </u>	$\bot$					<del> </del>		
					<u> </u>		$\perp$					1		
	<u> </u>			_	<u> </u>									
	l				<u> </u>							<u> </u>	<del></del>	
		O	THI	ER I	DO	CUM	IEN	TS (Inclu	ıding Author, T	itle, Date, P	ertinent Pag	es, Etc.)		
		Gas	hle	r,	Α.	& :	Suk	hatme,	V. Egr-1: p	rototype	of a zind	c finge	r fan-li	
J.H.		of transcription factors. Prog. Nucl. Acids Res. and Molec. Bio												
		50, 191-224 (1995)												
1.0														
(		Nguyen, H., Hoffman-Lieberman, B. & Liebennann, D. Egr-1 is essentia												
}		for and restricts differentiation along the macrophage cell lineage												
		Cel	1 7	72,	19	7-2	09	(1993)	$\mathcal{J}$					
1	Ĺ.													
	1	Yan		S - F		et	al	. Tiss	sue factor t	ranscrip	tion driv	en by	Egr-1 is	
		Yan, S-F., et al. Tissue factor transcription driven by Egr-1 is critical mechanism of murine pulmonary fibrin deposition in hypoxia												
									8298-8303 (				<del>-</del>	
										·				
	+													
											<del></del>	<del> </del>		
	l .	l												

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next



FORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



Form PTO-1449

## U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 0575/62683/JPW/JML Serial No. 09/648,389

Applicant

David J. Pinsky, et al.

Filing Date

August 25, 2000

Group

JUN 1 1 2001

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

okada, K., et al. Potentiation of endogenous fibrinolysis and rescue from lung ischemia-reperfusion injury in IL-10-reconstituted IL-10 null mice. J. Biol. Chem. epub ahead of print (2000) Lee, S., et al. Early expression of angiogenesis factors in acute myocardial ischemia. New Engl J Med 342, 626-633 (2000) Liu, P., et al. Role of endogenous nitric oxide in TNF-lpha and IL-1etageneration in hepatic ischemia-reperfusion. Shock 13, 217-223 (2000) Mechtcheriakova, D., et al. VEGF-induced tissue factor expression in endothelial cells is mediated by Egr-1. Blood 93, 3 811-3123 (1999) Khachigian, L., Lindner, V., Williams, A. & Collins, T. Egr-l-induced endothelial gene expression: a common theme in vascular injury. Science 271, 1427-1431 (1996)

EXAMINER OF

DATE CONSIDERED 15 7

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.